STAT1 and neoplasm: In vitro studies demonstrate type II IFN-induced STAT1 activation results in upregulation of PD-L1 expression on tumor cells, thereby inhibiting T cell and natural killer cell-mediated tumor cell killing (Liu et al. 2007; Bellucci et al. 2015).